NeoGenomics Plans to Share Third Quarter Financial Results
NeoGenomics, Inc. (NASDAQ: NEO), a renowned name in oncology testing services, is gearing up to deliver its financial results for the third quarter of 2024. This presentation is set to take place before the opening of the U.S. stock markets, specifically on an upcoming Tuesday in early November.
Management Discussion
After announcing their Q3 results, company management will conduct a comprehensive discussion via a webcast and conference call at 8:30 a.m. ET. This session is aimed at providing stakeholders with insights into the financial outcomes and key developments that have taken place within the company.
Accessing the Webcast
Individuals interested in joining the live discussion can conveniently access it through the Investor Relations section of the NeoGenomics website. The webcast will also be available for replay shortly after the conclusion of the call, ensuring that stakeholders can stay informed even if they cannot attend live.
Telephone Participation
For those preferring to join the conversation over the phone, access can be gained by dialing in at least five minutes early. Domestic listeners can use (888) 506-0062, while international participants can reach out at (973) 528-0011. The participant access code for this event is 676597.
About NeoGenomics
NeoGenomics, Inc. has emerged as a leader in cancer genetics testing, offering an extensive range of oncology-focused tests that are vital for the accurate diagnosis and treatment of cancer. Their commitment to enhancing patient care is reflected in their comprehensive service menu, which supports physicians' efforts in managing cancer diagnoses.
Pharmaceutical Services Division
In addition to patient services, NeoGenomics has a dedicated Pharma Services Division that caters specifically to pharmaceutical companies engaged in clinical trials and drug development. This division plays a crucial role in advancing oncology treatments and therapies by providing essential testing and insights.
Laboratories and Facilities
Headquartered in Fort Myers, Florida, NeoGenomics operates several CAP accredited and CLIA certified laboratories. These facilities provide full-service sample processing and are strategically located across different states, including Aliso Viejo and San Diego in California, Research Triangle Park in North Carolina, and Houston in Texas. Additionally, they maintain a laboratory in Cambridge, United Kingdom, to cater to their international clientele.
Serving Diverse Needs
NeoGenomics serves a wide array of clients, including pathologists, oncologists, academic institutions, hospital systems, and pharmaceutical firms. Their expansive reach extends beyond the United States, impacting pharmaceutical companies in both Europe and Asia.
Frequently Asked Questions
What is the date for NeoGenomics' Q3 2024 financial results?
NeoGenomics plans to report its Q3 2024 financial results on an upcoming Tuesday in early November.
How can I join the Q3 financial results webcast?
The webcast will be accessible through the Investor Relations section of the NeoGenomics website.
What is the access code for the telephone call?
The participant access code for the call is 676597.
Where are NeoGenomics laboratories located?
NeoGenomics has laboratories in several states including Florida, California, North Carolina, and Texas, as well as a facility in the United Kingdom.
Who does NeoGenomics serve?
NeoGenomics serves a variety of clients, including pathologists, oncologists, academic centers, hospital systems, and pharmaceutical companies across the globe.
